期刊文献+

普拉克索治疗帕金森病伴发抑郁障碍临床疗效与安全性 被引量:17

下载PDF
导出
摘要 目的评价普拉克索片剂治疗帕金森病(Parkinson's disease,PD)伴发抑郁障碍患者的临床疗效和安全性。方法对46例帕金森病伴发抑郁障碍患者随机分为两组,观察组以普拉克索(pramipexole)4.5mg/d治疗,对照组以美多芭750mg/d和帕罗西汀20mg/d治疗,观察12周。每4周评定1次,统一帕金森病评定量表(UPDRSⅢ)、汉密顿抑郁量表(HAMD)和临床总体印象量表(CGI)以衡量临床疗效,第12周末评定不良反应量表(TESS)以评价其安全性。然后进行组间比较。结果两组的HAMD、UPDRSⅢ总分、CGI-SI治疗后显著低于治疗前(P<0.05,P<0.01);治疗前和治疗4~8周末的HAMD总分、UPDRSⅢ总分、CGI-SI两组间差异无显著性(P>0.05),但第12周末时观察组HAMD总分显著高于对照组(P<0.05)、UPDRSⅢ总分显著低于对照组(P<0.05)。两组的不良反应发生频率相似(P>0.05)。结论普拉克索治疗帕金森病伴发抑郁障碍较安全有效,尽管其抗抑郁效应稍差但抗运动症状的效果较优。
出处 《广东医学》 CAS CSCD 北大核心 2010年第7期908-910,共3页 Guangdong Medical Journal
  • 相关文献

参考文献3

二级参考文献27

  • 1温洪波,张振馨,罗毅,陈生弟,蒋雨平,张小英,孙相如,王新德,姚晨.普拉克索治疗帕金森病的多中心、随机、双盲、溴隐亭对照临床疗效和安全性研究[J].中华神经科杂志,2006,39(9):604-608. 被引量:63
  • 2Mizuno Y,Yanagisawa N,Kuno S,et al.Randomized,doubleblind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.Mov Disord,2003,18:1149-1156.
  • 3Pinter MM,Rutgers AW,Hebenstreit E,et al.An open-label,multicentre clinical trial to determine the levodopa dose-sparing capacity of Pramipexole in patients with idiopathic Parkinson's disease.J Neural Transm,2000,107:1307-1323.
  • 4Reichmann H,Brecht MH,Koster J,et al.Pramipexole in routine clinical practice:a prospective observational trial in Parkinson's disease.CNS Drugs,2003,17:965-973.
  • 5Holloway RG,Shoulson I,Fahn S,et al.Pramipexole vs levodopa as initial treatment for Parkinson's disease:a 4-year randomized controlled trial.Arch Neurol,2004,61:1044-1053.
  • 6Linazasoro G,Spanish Dopamine Agonists Study Group.Conversion from dopamine agoists to Pramipexole.An open-label trial in 227 patients with advanced Parkinson's disease.J Neurol,2004,251:335-339.
  • 7Gu M,Iravani MM,Cooper JM,et al.Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms.J Neurochem,2004,91:1075-1081.
  • 8Asanuma M,Miyazaki I,Diaz-Corrales FJ,et al.Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopaminesemiquinone generated in vitro.Neurol Res,2005,27:533-539.
  • 9Moller JC,Oertel WH,Koster J,et al.Long-term efficacy and safety of pramipexole in advanced Parkinson's disease:results from a European multicenter trial.Mov Disord,2005,20:602-610.
  • 10Mierau J,Schingnitz G.Biochemical and Pharmacological studies on Pramipxole,a potent and selective D2 receptor agonist.Eur J Pharmacol,1992,215:161-170.

共引文献78

同被引文献104

引证文献17

二级引证文献129

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部